Abstract:

Objectives: Although blood transfusion involves many risks, it is a life-saving tissue/organ transplantation. The decision of transfusion, which is a valuable and expensive form of treatment, should be taken meticulously, and patients and products should be followed very carefully. The aim of this study is to retrospectively analyze the blood and blood product data used in our hospital between 2016 and 2020. Materials and Methods: Transfusion center data between 2016 and 2020 at our hospital were analyzed retrospectively. Results: Seven thousand two hundred and eighty-two patients, of whom 74.7% were male and 25.3% were female, who were planned for blood component transfusion were included. The mean age of the patients was 60.94±1.4 years. The most common blood groups were determined as A Rh+ and O Rh+. Erythrocyte suspension (65.9%), fresh frozen plasma (22.4%), apheresis platelet suspension (5.8%) were found to be the most commonly used blood components. The cost of supplying 30,435 units of blood components to the transfusion center was determined as 5,563,335 TL while the cost associated with the discard of 643 units of blood products was determined as 29,728 TL. The discard rate was determined as 2.11%. Conclusion: After transfusion, reactions and undesirable effects can be seen, and the use of blood products is an application that should be evaluated in detail in terms of cost. In this context, more detailed cost-effectiveness studies are needed.

Keywords: